Quote:

---

You don't pay 30x revenue for a 15 year patent.

---

Actually, I do think a 30x or more multiple of EARNINGS is possible and quite likely. Others have discussed (some time ago) the various ways that the patent protection can be extended. And, if CYDY does in fact become a BP, they will have the opportunity to research new drugs, as well as acquire other drugs.

My point is that COVID (as you went on to mention) is not likely to be a large indication for a long period of time.

COVID, in my opinion, will serve to SUPER charge all of the indications of Leronlimab. And, if they are as successful as we hope, that will create the high share prices we all dream about.